CTOs on the Move


 
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to pioneer new products with a mission to dramatically improve the lives of patients with severe autoimmune and inflammatory diseases who continue to suffer with high unmet medical needs.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.equilliumbio.com
  • 2223 Avenida De La Playa Suite 105
    La Jolla, CA USA 92037
  • Phone: 858.412.5302

Executives

Name Title Contact Details

Funding

Equillium raised $30M on 02/04/2021

Similar Companies

Ontera

Our platforms use silicon nanopore chips and proprietary biochemistry to accurately detect and differentiate single molecules. We will help transform point-of-care testing and third generation sequencing.

Isoflex

Isoflex is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AVI BioPharma

AVI BioPharma, Inc. is a Bothell, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Entrada Therapeutics

Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company`s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system.

Myriant Technologies

At Myriant, we know there`s a better, greener way to produce the products people use every day. And we`re realizing that vision—displacing barrels of petroleum by manufacturing and selling high-value chemicals made from renewable, sustainable feedstocks. As companies and consumers look for ways to reduce their carbon footprint and transition away from petroleum`s price volatility, Myriant has the solution: our proven technology platform and strategic feedstock selection enable Myriant to deliver high-quality, high-performing, green chemicals at a competitive, more-predictable cost versus petroleum-based chemicals without the need for government subsidies. That`s what we call a sustainable advantage.